Charles River Associates Releases Updated HTA Comparison Report

Washington, D.C., Brussels (June 17, 2014) — Charles River Associates today announced the release of a report at the HTAi Annual Meeting titled “A Comparative Analysis of the Role and Impact of Health Technology Assessment.”  The report, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA), updates a previous study conducted in 2011. 

Patient Reported Outcomes as a Means to Reaching Effective Quality Measurement

06.17.14 | By

A recent Roundtable in Washington D.C. underscored why, with the growing focus on value-based payment in health care, it’s more important than ever to focus on the patient. We can’t advance patient-centered care if we aren’t measuring and incentivizing what matters to patients. We have begun to see this shift in the premarket arena via patient-focused drug development and in comparative effectiveness research at the Patient-Centered Outcomes Research Institute.

A Mother’s View: Value and Cost of Health Care

06.17.14 | By

Over the last three years, I have had two c-sections – one for the birth of my 3-year old daughter and the other for the birth of my six-month old twins.  Fortunately, I have good health insurance coverage through my employer and didn’t have to pay a lot out of pocket for these necessary procedures. The more than $20,000 price tag for the single procedure was almost fully covered and I was happy that I could focus all of my attention on my newborn babies rather than figure out how I’m going to pay my  bills.

State “Right-to-Try” Legislation, While Well-Intentioned, Is Unlikely to Achieve Goal of Bringing Safe and Effective New Medicines to Patients

06.14.14 | By

The development of innovative, safe, and effective medicines for serious or life-threatening diseases represents an urgent and unique challenge that requires special attention.

Week in Review: The Obstacles to Patient Care Under HIX

06.13.14 | By

For our nation’s most vulnerable patients, access to necessary medicines to treat and even cure the diseases they are battling every day is critical. Improved patient health relies on the innovative treatments, and this week we focused on the importance of ensuring those medicines make it into the hands of patients in need.

Working Together for the Greater Good: The Current State of the Collaborative Research Ecosystem in Oncology

06.12.14 | By

Keeping the spirit of innovation alive in the oncology field is paramount to future scientific advances and finding cures. An essential element of innovation is collaboration. Relevant stakeholders coming together and pooling collective knowledge together can ignite the fire that becomes the next big thing to improve the lives of cancer patients.

High Cost of Medicines in Health Insurance Exchange Plans Is Harming Patients

06.12.14 | By

PhRMA President and CEO John J. Castellani recently joined several patient organizations to raise concerns about patients’ access to medicines in the new health insurance exchanges. They discussed findings from a new report by Avalere, commissioned by PhRMA, which shows that many patients, particularly those with chronic disease, are facing exorbitant out-of-pocket costs to access the prescription medicines they need to manage their conditions.

Patients’ Lack of Access to Medicines in Exchanges in Three Charts

06.12.14 | By

All patients should have access to the medicines they need to manage their diseases, enabling them to live fuller, healthier, more productive lives. Unfortunately, recently-released data paints a very troubling picture of patients’ access to medicines in the new health insurance exchanges.  Too often patients are being forced to pay exorbitant out-of-pocket costs for live-saving medicines that not only improve patients’ health and quality of life, but help prevent unnecessary hospitalizations, ER visits, and costly medical procedures.

Some Health Insurance Exchange Plans Put All Treatments for Certain Diseases on Top Cost-Sharing Tier

06.11.14 | By

This morning at the National Press Club, PhRMA CEO John J. Castellani joined patient groups to release new research from Avalere Health.

Big Data, Innovation and the Individual Experience Come Together to Put Patients First

06.11.14 | By

For millions of cancer patients and many others suffering from a chronic disease, access to new innovative treatments is critical. As an industry, we strongly believe that all patients should have access to the medicines they need to live long and healthy lives. Equally important, as discussions around health care costs continue, we must ensure that patients remain at the center of everything we do.


Subscribe to RSS - Opinion